You are here: Industry Insights > Bevacizumab

News List

Prestige BioPharma Releases Positive Results from Phase I Study of HD204, Biosimilar Candidate to Bevacizumab b3cnewswire
July 09, 2019
Prestige BioPharma Releases Positive Results from Phase I Study of HD204, Biosimilar Candidate to Bevacizumab.
Innovent declares positive result of IBI305, biosimilar to Avastin biospectrumasia
December 17, 2018
“Anti-angiogenic drugs are effective anti-tumor treatments, but as of yet there are no approved bevacizumab biosimilars in China.
FDA Approves Atezolizumab with Chemotherapy and Bevacizumab for First-Line Treatment of Metastatic Non-Squamous NSCLC americanpharmaceuticalreview
December 10, 2018
On December 6, 2018, the Food and Drug Administration approved atezolizumab (TECENTRIQ, Genentech, Inc.), in combination with bevacizumab, paclitaxel, and carboplatin .....
Roche pulls extended use application for kidney cancer drug pharmaphorum
November 26, 2018
Roche has withdrawn an application to the European Medicines Agency (EMA) for an expanded use for its immunotherapy drug, Tecentriq....
Roche withdraws Tecentriq combo application in first-line renal cell carcinoma pharmafile
November 20, 2018
The EMA has revealed that Roche has chosen to withdraw its marketing application for immunotherapy Tecentriq (atezolizumab) in combination with Genentech’s Avastin
JHL Biotech Gets Positive CHMP Scientific Advice for Bevacizumab Biosimilar biospectrumasia
August 13, 2018
JHL Biotech Receives Positive CHMP Scientific Advice for Global Phase III Clinical Trial of Proposed Bevacizumab Biosimilar to Treat Lung Cancer
Study reveals huge improvement for severe HHT patients after bevacizumab treatment europeanpharmaceuticalreview
February 01, 2018
A new study reveals the efficacy and safety of using intravenous bevacizumab to treat patients with severe hereditary haemorrhagic telangiectasia (HHT). Successful results suggest it should be used as a first-line therapy.

Previous page 1 2 3 Next page